Market reactionShares fell 10% on Nov 5.
iBio develops long-acting antibodies for obesity and heart-lung disease; IBIO-600 is in a Phase 1 trial, and its lead candidate IBIO-610 has not yet been tested in people. Nothing is approved.
IBIO-610 blocks Activin E, a liver hormone linked to fat storage. In obese monkeys, one dose suppressed active Activin E for eight weeks, and with semaglutide 93% of weight lost was fat versus 77% on semaglutide alone. These were small animal studies. iBio plans an IND-equivalent filing in the second half of 2026 and first human dosing in early 2027. IBIO-600, a myostatin antibody, finished single-dose testing; cash of $88 million lasts into fiscal 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: IBIO-610 reaches human testing
Does IBIO-610 enter human testing on schedule after its IND-equivalent filing?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
IBIO-610 has only animal data so far; first human dosing is planned for 2027
IBIO-610's first-in-class Activin E antibody targets obesity and T2D; the thesis turns on whether preclinical fat-selective signals translate to human efficacy in Phase 1
IBIO bets on a first-in-class Activin E antibody with a projected 100-day half-life to carve differentiated obesity positioning from GLP-1 incumbents — Phase 1 human data is the test
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Gastrointestinal cancers, Other cancers, Lung and respiratory diseases, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
10 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.